Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells

Allen Y. Chung, Qingsheng Li, Sarah J. Blair, Magdia De Jesus, Kristen L. Dennis, Charles Levea, Jin Yao, Yijun Sun, Thomas F. Conway, Lauren P. Virtuoso, Nicholas G. Battaglia, Stacia Furtado, Edith Mathiowitz, Nicholas J. Mantis, Khashayarsha Khazaie, Nejat K. Egilmez

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model of spontaneous gastrointestinal polyposis, that site-specific uptake of orally administered IL10 microparticles ameliorates local and systemic disease to enhance survival. Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutralization of disease-promoting FoxP3+ RoRyt+ IL17+ pathogenic T-regulatory cells (pgTreg), with a concomitant restoration of FoxP3+ RoRyt- IL17- conventional T-regulatory cells (Treg). These findings provide a proof-of-principle for the ability of an oral biologic to restore immune homeostasis at the intestinal surface. Furthermore, they implicate local manipulation of IL10 as a tractable therapeutic strategy to address the inflammatory sequelae associated with mucosal premalignancy.

Original languageEnglish (US)
Pages (from-to)5377-5385
Number of pages9
JournalCancer Research
Volume74
Issue number19
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Regulatory T-Lymphocytes
Interleukin-10
Homeostasis
Therapeutics
Pathology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Chung, A. Y., Li, Q., Blair, S. J., De Jesus, M., Dennis, K. L., Levea, C., ... Egilmez, N. K. (2014). Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. Cancer Research, 74(19), 5377-5385. https://doi.org/10.1158/0008-5472.CAN-14-0918

Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. / Chung, Allen Y.; Li, Qingsheng; Blair, Sarah J.; De Jesus, Magdia; Dennis, Kristen L.; Levea, Charles; Yao, Jin; Sun, Yijun; Conway, Thomas F.; Virtuoso, Lauren P.; Battaglia, Nicholas G.; Furtado, Stacia; Mathiowitz, Edith; Mantis, Nicholas J.; Khazaie, Khashayarsha; Egilmez, Nejat K.

In: Cancer Research, Vol. 74, No. 19, 01.10.2014, p. 5377-5385.

Research output: Contribution to journalArticle

Chung, AY, Li, Q, Blair, SJ, De Jesus, M, Dennis, KL, Levea, C, Yao, J, Sun, Y, Conway, TF, Virtuoso, LP, Battaglia, NG, Furtado, S, Mathiowitz, E, Mantis, NJ, Khazaie, K & Egilmez, NK 2014, 'Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells', Cancer Research, vol. 74, no. 19, pp. 5377-5385. https://doi.org/10.1158/0008-5472.CAN-14-0918
Chung, Allen Y. ; Li, Qingsheng ; Blair, Sarah J. ; De Jesus, Magdia ; Dennis, Kristen L. ; Levea, Charles ; Yao, Jin ; Sun, Yijun ; Conway, Thomas F. ; Virtuoso, Lauren P. ; Battaglia, Nicholas G. ; Furtado, Stacia ; Mathiowitz, Edith ; Mantis, Nicholas J. ; Khazaie, Khashayarsha ; Egilmez, Nejat K. / Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. In: Cancer Research. 2014 ; Vol. 74, No. 19. pp. 5377-5385.
@article{17caf1cd7e3f4be1a43a63195de9d518,
title = "Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells",
abstract = "Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model of spontaneous gastrointestinal polyposis, that site-specific uptake of orally administered IL10 microparticles ameliorates local and systemic disease to enhance survival. Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutralization of disease-promoting FoxP3+ RoRyt+ IL17+ pathogenic T-regulatory cells (pgTreg), with a concomitant restoration of FoxP3+ RoRyt- IL17- conventional T-regulatory cells (Treg). These findings provide a proof-of-principle for the ability of an oral biologic to restore immune homeostasis at the intestinal surface. Furthermore, they implicate local manipulation of IL10 as a tractable therapeutic strategy to address the inflammatory sequelae associated with mucosal premalignancy.",
author = "Chung, {Allen Y.} and Qingsheng Li and Blair, {Sarah J.} and {De Jesus}, Magdia and Dennis, {Kristen L.} and Charles Levea and Jin Yao and Yijun Sun and Conway, {Thomas F.} and Virtuoso, {Lauren P.} and Battaglia, {Nicholas G.} and Stacia Furtado and Edith Mathiowitz and Mantis, {Nicholas J.} and Khashayarsha Khazaie and Egilmez, {Nejat K.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-14-0918",
language = "English (US)",
volume = "74",
pages = "5377--5385",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells

AU - Chung, Allen Y.

AU - Li, Qingsheng

AU - Blair, Sarah J.

AU - De Jesus, Magdia

AU - Dennis, Kristen L.

AU - Levea, Charles

AU - Yao, Jin

AU - Sun, Yijun

AU - Conway, Thomas F.

AU - Virtuoso, Lauren P.

AU - Battaglia, Nicholas G.

AU - Furtado, Stacia

AU - Mathiowitz, Edith

AU - Mantis, Nicholas J.

AU - Khazaie, Khashayarsha

AU - Egilmez, Nejat K.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model of spontaneous gastrointestinal polyposis, that site-specific uptake of orally administered IL10 microparticles ameliorates local and systemic disease to enhance survival. Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutralization of disease-promoting FoxP3+ RoRyt+ IL17+ pathogenic T-regulatory cells (pgTreg), with a concomitant restoration of FoxP3+ RoRyt- IL17- conventional T-regulatory cells (Treg). These findings provide a proof-of-principle for the ability of an oral biologic to restore immune homeostasis at the intestinal surface. Furthermore, they implicate local manipulation of IL10 as a tractable therapeutic strategy to address the inflammatory sequelae associated with mucosal premalignancy.

AB - Immune dysregulation drives the pathogenesis of chronic inflammatory, autoimmune, and dysplastic disorders. While often intended to address localized pathology, most immune modulatory therapies are administered systemically and carry inherent risk of multiorgan toxicities. Here, we demonstrate, in a murine model of spontaneous gastrointestinal polyposis, that site-specific uptake of orally administered IL10 microparticles ameliorates local and systemic disease to enhance survival. Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutralization of disease-promoting FoxP3+ RoRyt+ IL17+ pathogenic T-regulatory cells (pgTreg), with a concomitant restoration of FoxP3+ RoRyt- IL17- conventional T-regulatory cells (Treg). These findings provide a proof-of-principle for the ability of an oral biologic to restore immune homeostasis at the intestinal surface. Furthermore, they implicate local manipulation of IL10 as a tractable therapeutic strategy to address the inflammatory sequelae associated with mucosal premalignancy.

UR - http://www.scopus.com/inward/record.url?scp=84907495388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907495388&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0918

DO - 10.1158/0008-5472.CAN-14-0918

M3 - Article

C2 - 25228656

AN - SCOPUS:84907495388

VL - 74

SP - 5377

EP - 5385

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -